Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.

e16557 Background: EpCAM is a tumor associated antigen which is frequently expressed in ovarian cancer. Recently, an autoantibody (AAB) against EpCAM has been identified in ovarian cancer patients. Autoantibodies are immunogene factors and might be of prognostic importance. We showed that disseminated tumor cells (DTC) in bone marrow carry the EpCAM antigen on their surface and correlate with poorer progression free survival (PFS). Here, we evaluated whether EpCAM-AABs have an impact on clinical parameters or the presence of DTC in ovarian cancer patients. Methods: EpCAM-AABs were determined in sera of 28 healthy voluntary age matched females and 62 patients with primary epithelial ovarian cancer before and after platinum-based chemotherapy using a recombinant EpCAM-epitope for antibody- detection by ELISA technique. Mean follow up time was 13 months. DTC in BM were detected by immunocytochemistry applying the pan cytokeratin antibody A45-B/B3. All samples exceeding the mean antibody titer of healthy controls plus 2 standard deviations were considered positive. Results: The antibody titer of healthy controls was 0.061 + 0.015. Using a cut-off value of 0.091, we found 9/62 (15%) ovarian cancer patients to be positive for EpCAM-AABs after first-line treatment. Interestingly, no positive AAB-titers were seen before therapy. Using the paired T-Test, we noted a significant posttherapeutic increase of AABs (CI 0.95, p < 0.0001). Analysis of PFS, FIGO stage, resection status, grading, age, sensitivity to platinum based chemotherapy and DTC did not reveal significant associations with positive EpCAM-AAB titers. Conclusions: The clinical course of ovarian cancer patients and the prevalence of DTC were not altered by EpCAM-AABs. Interestingly, we observed an increase of antibody-levels after first-line treatment. For further validation, we intend to extend our patient collective. In future, it might also be interesting to investigate the impact of AABs on response to targeted therapies against EpCAM. No significant financial relationships to disclose.

Download Full-text

IS BRCA MUTATIONAL STATUS A PREDICTOR OF PLATINUM-BASED CHEMOTHERAPY RELATED HEMATOLOGIC TOXICITY IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?

10.26226/morressier.5d2ee8eb1e09a6f49485acc5 ◽

2019 ◽

Author(s):

Federica Tomao ◽

Lucia Musacchio ◽

Di Mauro Federica ◽

Serena Maria Boccia ◽

Violante di Donato ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Hematologic Toxicity ◽

High Grade ◽

Serous Ovarian Cancer ◽

Mutational Status ◽

Platinum Based Chemotherapy

Download Full-text

627 SCOUT-1: prospective non-interventional study in BRCA/HRD tested ovarian cancer patients eligible for first-line platinum-based chemotherapy

10.1136/ijgc-2021-esgo.442 ◽

2021 ◽

Author(s):

EI Braicu ◽

R Glowik ◽

K Pietzner ◽

M Rose ◽

P Wimberger ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

First Line ◽

Interventional Study ◽

Platinum Based Chemotherapy

Download Full-text

Investigating reasons for discontinuation of first-line adjuvant chemotherapy among ovarian cancer patients in the midwestern United States.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e17523 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e17523-e17523

Author(s):

Kristin S. Weeks ◽

Sherri L. Stewart ◽

Michele West ◽

Ryan Carnahan ◽

Jacob Oleson ◽

...

Keyword(s):

United States ◽

Ovarian Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

The United States ◽

Comorbid Conditions ◽

First Line ◽

Midwestern United States ◽

Platinum Based Chemotherapy ◽

Line Chemotherapy

e17523 Background: Receipt of surgery and adjuvant chemotherapy greatly impact survival outcomes for ovarian cancer, the deadliest gynecologic malignancy with a high recurrence/progression rate. Most patients receive first-line, platinum-based chemotherapy. Platinum-based chemotherapy causes severe side effects, including nephrotoxicity and myelosuppression. Evidence for other chemotherapeutic agents is lacking and options are limited for women who cannot tolerate first-line chemotherapy. We aimed to determine the prevalence of premature first-line chemotherapy discontinuation and to detail reasons for discontinuation. Methods: We used the population-based cohort, Patterns of Ovarian Cancer Care and Survival in the Midwestern Region of the United States—a CDC Investigation, comprised of women diagnosed with histologically confirmed, stage IB-IV ovarian cancer in 2010-2012 in the Midwestern United States (i.e., Iowa, Kansas and Missouri) between the ages of 18 and 89 years. We limited the cohort to patients who received cancer-directed surgery and initiated adjuvant chemotherapy. Chemotherapy lines, completion, and reasons for discontinuation were abstracted from patient medical records by cancer registrars using standardized protocols. Results: Nineteen percent (N= 107/559) of ovarian cancer patients who initiated adjuvant chemotherapy did not complete first-line treatment. Reasons for chemotherapy discontinuation included toxicity or other kinds of intolerance (39%), poor quality of life or comorbid conditions (19%) or exhibited no response (17%) (Table). No significant differences were observed between gynecologic oncologists and non-gynecologic oncologist chemotherapy providers (p=0.109). Conclusions: One in 5 women who initiated did not complete first-line chemotherapy. Reasons were varied and suggested that lack of tolerance is not the only factor in discontinuation. Lack of response and the presence of comorbid conditions are considerations that can be taken into account during decision-making processes for treatment. More clinical research into additional chemotherapy options that may be useful in these patients is necessary.[Table: see text]

Download Full-text